SLS SELLAS Life Sciences Group, Inc.

Shares of Sellas Life Sciences Group Inc. (NASDAQ:SLS) nosedived by 16.6 percent in the third quarter of the year—from $14.76 on June 30 to $12.31 on Wednesday—as sentiment was dragged down by the delays and uncertainties surrounding the clinical results of its treatment candidate for acute myeloid leukemia (AML). In Wednesday’s trading alone, the stock […]

SELLAS Life Sciences Group, Inc. recently reported preclinical data at an AACR pancreatic cancer conference showing its CDK9 inhibitor SLS009 induced meaningful cancer cell death in MYC-amplified, daraxonrasib-resistant pancreatic ductal adenocarcinoma organoid models, both alone and in combinations. The findings highlight SLS009’s potential to address RAS inhibitor resistance and show synergistic effects when paired with BET inhibitor ZEN3694 at relatively low exposure levels. We’ll now...

SELLAS Life Sciences Group has delivered a very large 3 year return, which puts a spotlight on whether the current share price around US$11.51 still lines up with what its balance sheet is worth on paper. With that kind of move behind it and new cancer therapy data in play, the question now is how much value investors are effectively placing on SELLAS' book value. Over the past 3 years, the stock has gained roughly 7x. This makes the relationship between its recent share price performance...

SELLAS Life Sciences Group (SLS) presented new preclinical data on September 25, 2026, highlighting its CDK9 inhibitor SLS009 in pancreatic cancer organoid models at an AACR pancreatic cancer conference. SELLAS Life Sciences Group shares trade at US$11.51 after a 1-day share price return that declined 0.69%, extending a 30-day share price drop of 12.87%. Yet the 1-year total shareholder return is very large at more than 6x and the 3-year total shareholder return is also very large, hinting...

IOVA surged 77% and IBRX gained 11%, bucking biotech’s decline, while SLS fell 14% and VNDA slipped 7%.

SLS investors have been closely watching for two key developments: late-stage REGAL study data for the company’s GPS cancer vaccine in acute myeloid leukemia and a decision on whether SLS009 will advance into human trials for pancreatic cancer.

Sellas said earlier laboratory work showed activity against pancreatic cancer cells resistant to RAS-targeting drugs.

Novo Nordisk (NVO) will hold its 2026 Capital Markets Day in London on Monday.

The rally followed a Nant Capital-led financing worth up to $22.3 million, with $11.3 million raised at the initial close.

J&J’s recent deals include the $3.05 billion Halda acquisition and $1 billion Firefly purchase, while Pfizer’s Innovent deal is worth up to $10.5 billion.

ImmunityBio is attending major conferences in Seoul and New York, followed by several oncology events through November.

Its IBRX stake jumped 27.5% to 243,678 shares worth $2.13 million, bringing both positions’ combined value to $2.86 million.

SELLAS Life Sciences Group (NasdaqCM:SLS) will present new preclinical data on SLS009 in pancreatic ductal adenocarcinoma at the 2026 AACR Conference. Three abstracts on SLS009 have been accepted, focusing on its mechanism of action and activity in KRAS mutant pancreatic cancer models. The research is being carried out with a respected academic institution and adds detail on SLS009 within SELLAS Life Sciences Group's preclinical pipeline. Interest in SELLAS Life Sciences Group reflects a...

Three abstracts evaluating SLS009 have been accepted for poster presentations at the AACR Conference on Pancreatic Cancer later in September.

Sellas is gaining Wall Street’s attention as clinical progress, upcoming catalysts, and positive analyst sentiment strengthen the case for further upside.

Retail traders viewed the Merida acquisition as evidence that Big Pharma will pay rich premiums for immune-focused platforms.

Editor’s Note: The story has been refreshed with the latest market price action and a revised headline. Short seller BMF Capital disclosed a short position in SELLAS Life Sciences Group Inc., arguing the market has “dangerously overvalued” the biotech company...

In a post on LinkedIn on Monday, Angelos Stergiou said despite speculation and outside commentary ‘naturally’ increasing, the company will let the data speak for itself.

An AstraZeneca sales executive called the Phase 3 Regal trial a “game changer” for AML patients in their first or second complete remission.

Sellas Life Sciences (NASDAQ:SLS) saw its share price decline by 13.15 percent on Friday to close at $13.21 apiece, as investors turned increasingly concerned about the company’s silence about its treatment candidate for acute myeloid leukemia (AML). The drop was triggered by a report from a Germany-based news site that the company has already hit […]

ARK sees a path toward custom cancer treatments for every patient, though current costs of $200,000-$300,000 remain a major hurdle.

On Wednesday, the U.S. Food and Drug Administration approved RASONQUE, a once-daily pill for adults with metastatic pancreatic cancer who have already tried chemotherapy or cannot take multi-drug regimens.

Virginia Retirement System disclosed SLS and IBRX stakes worth nearly $909,000 combined.

Sellas shares reached a swing high of $15.88 in late June before tumbling 42% to a July low of $9.19.

A German report claimed Regal hit its 80th event, but Sellas has not confirmed it.

The stock has gained over 20% in the past five days, marking its best week since early July.

SELLAS Life Sciences Group, Inc. reported second-quarter 2026 results showing a net loss of US$9.61 million and basic loss per share from continuing operations of US$0.05, with first-half 2026 net loss reaching US$18.01 million and basic loss per share of US$0.10. Despite wider net losses in dollar terms, the company’s loss per share narrowed year on year, pointing to the impact of share count changes amid heightened interest in its Phase 3 GPS cancer vaccine program following positive...

SELLAS Life Sciences Group (SLS) is drawing fresh attention as investors reassess immune based cancer therapy stocks following Moderna and Merck’s Phase 3 cancer vaccine update and the broader oncology rally it helped spark. See our latest analysis for SELLAS Life Sciences Group. At a latest share price of $13.40, SELLAS Life Sciences Group has seen a 72.24% 90 day share price return and a very large 1 year total shareholder return. This suggests momentum has been building as attention shifts...

SELLAS Life Sciences Group stock has posted a very large 3 year return while the latest valuation checks flag it as expensive rather than a clear bargain. Over the past 3 years, SELLAS Life Sciences Group has delivered a gain of about 7.9x, which sets a high bar for any further upside to be justified. Progress toward key milestones in the REGAL AML trial and the advancement of SLS009 in difficult cancer indications can support high growth expectations, yet the usual risks around clinical...

Moderna soared 177% Wednesday, while Merck gained 13% and the rally spread to BioNTech, Arcturus, Tempus AI and Novavax.

Maxim Group described Moderna’s positive late-stage melanoma results as a “win for cancer vaccines,” arguing the surge in Moderna shares should support SELLAS if its key trial succeeds.

A separate pediatric study delivered “striking” WT1 vaccine results, supporting GPS’s scientific rationale, the company's CEO said.

Stergiou highlighted a Phase 2 study published in the Blood Advances journal that evaluated a maintenance therapy in 17 children with hard-to-treat acute leukemia following stem-cell transplants.

Goldman increased its stake in Sellas by 5.2% to 585,035 shares, worth $8.64 million.

Vanguard held SLS and IBRX positions worth a combined $259 million at quarter-end.

Alliance Global lifted its SLS price target to $35 from $25, implying nearly 200% upside, and maintained a ‘Buy’ rating.

Alliance Global analyst James Molloy said SLS009, which is being developed for acute myeloid leukemia, could potentially be used to treat additional cancers.

The biotech, focused on novel cancer therapies, reported a net loss of $9.6 million, or $0.05 per share, for the quarter ended June 30.

Wall Street expects no quarterly revenue and a GAAP loss of $0.04 per share, narrowing from $0.05 previously.

IBRX and SLS align with Big Pharma’s cancer push, fueling retail partnership and buyout speculation.

In recent months, Daiwa Securities very sharply increased its stake in SELLAS Life Sciences Group by 100,300 shares, while SELLAS reported that its Phase 3 REGAL trial in acute myeloid leukemia had reached 78 of the 80 events required for final analysis and held an estimated US$138.30 million in cash at the end of June. This combination of an imminent pivotal trial readout and a strengthened institutional presence highlights how clinical and balance-sheet milestones are converging for...

SELLAS Life Sciences Group (SLS) is back in focus as its Phase 3 REGAL trial in acute myeloid leukemia nears final analysis and Daiwa Securities reports a very large increase in its shareholding. See our latest analysis for SELLAS Life Sciences Group. The recent clinical update and Daiwa’s larger stake come after a sharp move in SELLAS Life Sciences Group’s share price, with a 1-day share price return of 12.09% and a year-to-date share price return of 157.93%, while the 1-year total...

SELLAS Life Sciences Group has delivered a very large 3 year return, yet its recent share price swings and a low overall value score suggest the stock may now be pricing in a lot of optimism. The stock has returned about 6.1x over the past 3 years, which sets a high bar for any further upside to be justified by fundamentals. Future clinical and commercial progress can support the current valuation, but execution risk and funding needs typical for early stage biopharma may limit how much...

Vontobel cut its holding by 16% but retained SLS shares worth $2.17 million.

Opus Capital held 385,604 shares worth about $5.69 million after increasing its position by 11.3%.

A new Schedule 13G filing showed Vanguard Capital Management owned 9.67 million SLS shares as of June 30, 2026.

New York State Common Retirement Fund boosted its holding by 70%, while Commonwealth and Axxcess each raised stakes by about 17%.

An arbitrator recently dismissed Sellas’ claims against 3D Medicines and ordered about $1 million in legal-cost payments.

Sellas estimated cash and cash equivalents of $138.3 million as of June 30.

CEO Angelos Stergiou said recently on “FOX & Friends” that AI and precision medicine could speed drug development and improve patient selection.